Follow us on Twitter
twitter icon@FreshPatents


Hla patents

      

This page is updated frequently with new Hla-related patent applications.




 Neil3 peptides and vaccines including the same patent thumbnailNeil3 peptides and vaccines including the same
The present invention provides isolated peptides or the fragments derived from seq id no: 45, which bind to an hla antigen and induce cytotoxic t lymphocytes (ctl). The peptides may include the above mentioned amino acid sequence with substitution deletion, or addition of one, two, or several amino acids sequences.
Oncotherapy Science, Inc.


 Quinazolinone derivatives for use in the treatment of chlamydiales infections patent thumbnailQuinazolinone derivatives for use in the treatment of chlamydiales infections
Wherein, r1, r2, r3, r4 and p are as defined in claim 1.. .

 Benzodiazepine derivatives for use in the treatment of chlamydiales infections patent thumbnailBenzodiazepine derivatives for use in the treatment of chlamydiales infections
Wherein r1, r2, r3 and ar are as defined in claim 1.. .

 Adamantane or pinene derivatives for use in the treatment of chlamydiales infections patent thumbnailAdamantane or pinene derivatives for use in the treatment of chlamydiales infections
Wherein w, l1, l2 and ar are as defined in claim 1.. .

 Nucleic acid probe with single fluorophore label bound to internal cytosine for use in loop mediated isothermal amplification patent thumbnailNucleic acid probe with single fluorophore label bound to internal cytosine for use in loop mediated isothermal amplification
The disclosure relates to novel probes for use in lamp detection methods. The probes contain a single fluorophore label bound to an internal cytosine residue of the probe.
Mast Group Limited


 Methods of detecting chlamydia and gonorrhea and of screening for infection/inflammation based on genomic copy number patent thumbnailMethods of detecting chlamydia and gonorrhea and of screening for infection/inflammation based on genomic copy number
Compositions and methods for detecting chlamydia trachomatis (ct) and neisseria gonorrhoeae (ng) are provided. The present invention also provides methods and compositions for screening for infection/inflammation based on genomic copy number.
Cepheid


 Methods of detecting antibodies specific for denatured hla antigens patent thumbnailMethods of detecting antibodies specific for denatured hla antigens
The invention is directed to methods of screening for hla antibodies comprising detecting antibodies specific for native hla antigens and denatured hla antigens. The invention also provides for methods of removing antibodies specific for denatured hla antigens or antibodies specific for native hla antigens from a serum sample.
One Lambda, Inc.


 Compositions and methods for providing hematopoietic function patent thumbnailCompositions and methods for providing hematopoietic function
The present invention relates to methods and compositions for providing hematopoietic function to human patients in need thereof, by selecting a pool of expanded human cord blood stem/progenitor cell samples for administration to the patient, wherein the samples in the pool collectively do not mismatch the patient at more than 2 of the hla antigens or alleles typed in the patient; and administering the selected pool of expanded human cord blood stem/progenitor cell samples to the patient. Methods for obtaining the pools of expanded human cord blood stem/progenitor cell samples, banks of frozen pools of expanded human umbilical cord blood stem/progenitor cell samples, and methods for producing such banks are also provided herein..
Fred Hutchinson Cancer Research Center


 Chlamydia antigens patent thumbnailChlamydia antigens
The invention provides chlamydia antigens for use in the treatment, prevention and/or diagnosis of chlamydia infection. In particular, the invention provides antigens ct733, ct153, ct601, ct279, ct443, ct372, ct456, ct381, ct255, ct341, ct716, ct745, ct387, ct812, ct869, ct166, ct175, ct163, ct214, ct721, ct127, ct043, ct823 and/or ct600 from c.
Glaxosmithkline Biologicals Sa


 Compositions for and methods of identifying antigens patent thumbnailCompositions for and methods of identifying antigens
Replicable libraries having discrete members in defined locations for screening for antigens to a pathogenic organism are provided. Also provided are methods for using such libraries as well as a specific antigen, ct788, which induces t-cell activation during a chlamydia infection..
President And Fellows Of Harvard College


Omv vaccines

The invention is in the field of outer membrane vesicles (omv) and their uses. More particularly the present invention provides omv obtained from a bacterium being an ompa mutant and/or a mutant in one or more components of the tolpal complex and presenting a heterologous antigen on its surface.
Novartis Ag

Chlamydia antigen compositions and uses thereof

The present invention provides in part fusion proteins derived from chlamydia spp. The present invention also provides in part methods for treating or preventing chlamydia infection using the fusion proteins..
The University Of British Columbia

Tumor vaccine

The invention relates to the fields of medicine, immunology, and oncology. More specifically, the invention relates to methods and compositions for inducing an immune response against a tumor in an animal subject.
University Of Miami

Polynucleotides for the amplification and detection of chlamydia trachomatis and neisseria gonorrhoeae

Polynucleotides useful for detecting chlamydia trachomatis and/or neisseria gonorrhoeae in a test sample, kits, a nucleic acid amplification method and detection method including the same.. .
Abbott Molecular Inc.

P2x7 modulators

The present invention is directed to a compound of formula (i) or (ia) the invention also relates to pharmaceutical compositions comprising compounds of formula (i) or (ia) and methods comprising administering of compounds of formula (i) or (ia) for treating rheumatoid arthritis, osteoarthritis, psoriasis, septic shock, allergic dermatitis, asthma, allergic asthma, mild to severe asthma, steroid resistant asthma, idiopathic pulmonary fibrosis, allergic rhinitis, chronic obstructive pulmonary disease; airway hyper-responsiveness, diseases of the nervous and neuro-immune system, acute and chronic pain states of neuropathic pain, inflammatory pain, spontaneous pain, opioid induced pain, diabetic neuropathy, postherpetic neuralgia, low back pain, chemotherapy-induced neuropathic pain, fibromyalgia, diseases involved with and without neuroinflammation of the central nervous system, mood disorders, major depression, major depressive disorder, treatment resistant depression, bipolar disorder, anxious depression, anxiety, cognition, sleep disorders, multiple sclerosis, epileptic seizures, parkinson's disease, schizophrenia, alzheimer's disease, huntington's disease, autism, spinal cord injury and cerebral ischemia/traumatic brain injury, stress-related disorders, diseases of the cardiovascular, metabolic, gastrointestinal and urogenital systems such as diabetes, diabetes mellitus, thrombosis, irritable bowel syndrome, irritable bowel disease, crohn's disease, ischemic heart disease, ischaemia, hypertension, cardiovascular disease, myocardial infarction, and lower urinary tract dysfunction such as incontinence, lower urinary tract syndrome, polycystic kidney disease, glomerulonephritis, skeletal disorders, osteoporosis, osteopetrosis, and glaucoma, interstitial cystitis, cough, ureteric obstruction, sepsis, amyotrophic lateral sclerosis, chaga's disease, chlamydia, neuroblastoma, tuberculosis, and migraine.. .
Janssen Pharmaceutica Nv

P2x7 modulators

The present invention is directed to a compound of formula (i) formula (i) the invention also relates to pharmaceutical compositions comprising compounds of formula (i) and methods comprising administering to a subject at least one compound selected from compounds of formula (i) for treating diseases mediated by p2x7 receptor activity, such as rheumatoid arthritis, osteoarthritis, psoriasis, septic shock, allergic dermatitis, asthma, allergic asthma, mild to severe asthma, steroid resistant asthma, idiopathic pulmonary fibrosis, allergic rhinitis, chronic obstructive pulmonary disease; airway hyper-responsiveness, diseases of the nervous and neuro-immune system, acute and chronic pain states of neuropathic pain, inflammatory pain, spontaneous pain, opioid induced pain, diabetic neuropathy, postherpetic neuralgia, low back pain, chemotherapy-induced neuropathic pain, fibromyalgia, diseases involved with and without neuroinflammation of the central nervous system, mood disorders, major depression, major depressive disorder, treatment resistant depression, bipolar disorder, anxious depression, anxiety, cognition, sleep disorders, multiple sclerosis, epileptic seizures, parkinson's disease, schizophrenia, alzheimer's disease, huntington's disease, autism, spinal cord injury and cerebral ischemia/traumatic brain injury, stress-related disorders, diseases of the cardiovascular, metabolic, gastrointestinal and urogenital systems such as diabetes, diabetes mellitus, thrombosis, irritable bowel syndrome, irritable bowel disease, crohn's disease, ischemic heart disease, ischaemia, hypertension, cardiovascular disease, myocardial infarction, and lower urinary tract dysfunction such as incontinence, lower urinary tract syndrome, polycystic kidney disease, glomerulonephritis, skeletal disorders, osteoporosis, osteopetrosis, and glaucoma, interstitial cystitis, cough, ureteric obstruction, sepsis, amyotrophic lateral sclerosis, chaga's disease, chlamydia, neuroblastoma, tuberculosis, and migraine.. .
Janssen Pharmaceutica Nv

Attenuated chlamydia vaccine

The invention provides vectors, attenuated pathogens, compositions, methods, and kits for use in preventing or treating infection by an infectious pathogen, especially chlamydia trachomatis. The vectors comprise the plasmid encoded ppg genes from chlamydia, ppg1, ppg2, ppg3, ppg5, ppg6, ppg7 and/or ppg8, but lack ppg4, a regulator of virulence associated genes.
The United States Of America,as Represented By The Secretary, Department Of Health & Human Services

Primer and probe sequences for detecting chlamydia trachomatis

The present invention relates to primers and probes that can be used in various assays to detect a new strain of chlamydia trachomatis. The invention further provides for the simultaneous detection of other diseases, especially neisseria gonorrhoeae..
Abbott Molecular Inc.

Methods of detecting chlamydia and gonorrhea and of screening for infection/inflammation based on genomic copy number

Compositions and methods for detecting chlamydia trachomatis (ct) and neisseria gonorrhoeae (ng) are provided. The present invention also provides methods and compositions for screening for infection/inflammation based on genomic copy number.
Cepheid

Tomm34 peptides and vaccines including the same

The present invention provides isolated peptides or the fragments derived from seq id no: 42, which bind to an hla antigen and induce cytotoxic t lymphocytes (ctl). The peptides may include one of the above mentioned amino acid sequences with substitution, deletion, or addition of one, two, or several amino acids sequences.
Oncotherapy Science, Inc.

Emp2 antibodies and their therapeutic uses

The present invention provides methods and compositions useful in the treatment or prevention of chlamydia infections and cancer. The methods and compositions inhibit the entry of chlamydia into a host cell expressing emp2 by interfering with the interaction between the chlamydia and emp2.
The Regents Of The University Of California

Method and its compositions for detection of nucleic acid target from biological samples and body fluids

Current invention is directed for rapid sample pretreatment method that allows highly sensitive and specific detection of target nucleic acid (eg human genomic dna, human pathogen genomic dna, human non-pathogen genomic dna) by amplification directly from crude unpurified biological samples lysates (eg human urine, saliva, blood, urethra and cervical swabs and other samples containing biological material). Invention is focused on the description of the biological sample pretreatment method that enables fast release of the genomic material from human and pathogen cells, components of what are compatible with the following nucleic acid amplification method.
Selfdiagnostics OÜ

Neil3 peptides and vaccines including the same

The present invention provides isolated peptides or the fragments derived from seq id no: 45, which bind to an hla antigen and induce cytotoxic t lymphocytes (ctl). The peptides may include the above mentioned amino acid sequence with substitution deletion, or addition of one, two, or several amino acids sequences.

Mutant forms of chlamydia htra

An immunogenic chlamydia htra protein, which has one or more mutations relative to wild-type chlamydia htra that result in a reduced or eliminated protease activity relative to the protease activity of wild-type chlamydia htra. Preferably, it is the serine protease activity that is reduced or eliminated..
Novartis Ag

Personalized cancer vaccines and adoptive immune cell therapies

Cancer antigens containing mutations in an expressed gene of cancer cells from a cancer patient are identified. Sequences from cancer cells obtained using a parallel sequencing platform are selected by comparing to the patient's normal genes or to normal genes from an hla-matched individual.
Persimmune, Inc.

Real-time pcr for the detection of pathogens

Disclosed herein are methods for detecting presence of one or more of acinetobacter baumannii, pseudomonas aeruginosa, klebsiella pneumoniae, toxoplasma gondii, moraxella catarrhalis, escherichia coli, shigella, staphylococcus aureus, pneumocystis jirovecii, chlamydia trachomatis, ureaplasma urealyticum, ureaplasma parvum, ureaplasma spp., bartonella spp., streptococcus agalactiae, and neisseria meningitidis nucleic acids in a sample, such as a biological sample obtained from a subject, or an environmental sample. This disclosure also provides probes, primers, and kits for detecting one or more of acinetobacter baumannii, pseudomonas aeruginosa, klebsiella pneumoniae, toxoplasma gondii, moraxella catarrhalis, escherichia coli, shigella, staphylococcus aureus, pneumocystis jirovecii, chlamydia trachomatis, ureaplasma urealyticum, ureaplasma parvum, ureaplasma spp., bartonella spp., streptococcus agalactiae, and neisseria meningitidis in a sample..
The Government Of The Usa As Represented By The Secretary Of The Dept Of Health And Human Services

Methods and compositions for treatment of chlamydial infection and related diseases and disorders

The present invention provides compositions and methods of use in the treatment/prevention of chlamydial infection and/or diseases and disorders associated with chlamydial infection in a subject.. .
Wake Forest University Health Sciences

Method of intracellular infectious agent detection in sperm cells

The present invention describes a method for investigating the presence of chlamydia, viruses and other infectious agents in spermatozoa, with the use of immunofluorescence in combination with flow cytometry. This method is used for the intracellular detection of microorganisms within sperm cells through the use of a dna easing procedure, as well as for the detection of microorganisms adherent to the surface of spermatozoa..

Compositions and methods for immunodominant antigens

Contemplated compositions, devices, and methods comprise immunodominant antigens from selected human pathogens (burkholderia pseudomallei, borrelia burgdorferi, brucella melitensis, chlamydia muridarum, coxiella burnetii, francisella tularensis, human herpes virus 1 and 2, mycobacterium tuberculosis, plasmodium falciparum, and vaccinia virus) can be used as a vaccine, as diagnostic markers, and as therapeutic agents. In particularly preferred aspects, the antigens have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and have a known association with a disease parameter..
Immport Therapeutics, Inc.

Chlamydia antigen compositions and uses thereof

The present invention provides in part peptides and polypeptides derived from chlamydia app. The present invention also provides in part methods for treating, preventing or diagnosing chlamydia infection using the peptides and polypeptides..
The University Of British Columbia

Products and methods

The invention relates to fungal cells and spores, as well as extracts of either, for use, in particular, in prevention or treatment of chlamydia, or helicobacter pylori or other infections, inflammation, inflammatory, lysosomal, acidic, sod- or igg or other immunoglobulin—peroxidases or hydrogen peroxide induced or other forms of oxidative damage, atherosclerosis, heart disease, stomach, intestinal and liver inflammatory conditions and their complications, promoting or stimulating regeneration or healing of wounds, burns, ulcers, or other forms of damaged or aged tissues, or in reducing elevated cholesterol and/or triglycerides levels in a preferred instance, the fungal cells or spores are those used in the manufacture of fungal fermented cheeses or other food stuff or beverages, particular fungal blue or white cheeses.. .
Ip Science Limited

Nanoantibodies, binding chlamydia trachomatis antigen, inhibition of infection induced by chlamydia trachomatis

A nanoantibody specifically binding surface antigen of chlamydia trachomatis and having seq id no:2 amino acid sequence is disclosed. A nanoantibody specifically binding surface antigen of chlamydia trachomatis and having seq id no:4 amino acid sequence is disclosed.

Real-time multiplex detection of three bacterial species responsible for sexually transmitted diseases

The invention relates to the detection of three different bacterial species which are responsible for sexually-transmitted diseases, i.e., chlamydia trachomatis (ct), neisseria gonorrhoeae (ng) and mycoplasma genitalium (mg). The invention more particularly relates to the detection of these three species in real-time pcr, in multiplex pcr and in real-time multiplex pcr.

Vaccines against chlamydia sp.

The present invention describes an efficient vaccine against a chlamydia trachomatis (ct). The vaccine is based on recombinant fusion molecules that are capable of generating a high titered neutralizing antibody response that is protective against various ct serovars.

Chlamydia-specific cd8+ t cells and methods of isolating

Isolated, chlamydia-specific, il-13 expressing cd8+ t cell clones are provided for understanding the biology of chlamydia infection and screening of therapeutics. Furthermore, methods are provided for isolating cd8+ t cells comprising the steps of infecting or identifying a naturally infected mammal with at least one species of chlamydia causing bacteria, allowing the bacteria to clear or for a t cell immune response to the natural infection, collecting immune splenocytes from the mammal, providing at least one antigen from a chlamydia-specific bacteria, and expanding and depleting the cd4+ t cell population or purifying the cd8 t cell population to isolate il-13 expressing cd8+ t cell clones..

Hjurp peptides and vaccines including the same

Isolated peptides derived from seq id no: 50 and fragments thereof that bind to an hla antigen and induce cytotoxic t lymphocytes (ctl) and thus are suitable for use in cancer immunotherapy are described herein. The inventive peptides encompass both the above mentioned amino acid sequences and modified versions thereof, provided they retain the requisite cytotoxic t cell inducibility of the original sequence.

Vaccines for chlamydia

The present invention relates to means and methods to protect against disease caused by bacteria belonging to the genus chlamydia. In particular, the present invention relates to isolated b- and t-cell epitopes derived from the major outer membrane protein of chlamydia psittaci which can be used against an infection with a species of the genus chlamydia.

Inhibitors of bacterial type iii secretion system

Organic compounds showing the ability to inhibit effector toxin secretion or translocation mediated by bacterial type iii secretion systems are disclosed. The disclosed type iii secretion system inhibitor compounds are useful for combating infections by gram-negative bacteria such as salmonella spp., shigella flexneri, pseudomonas spp., yersinia spp., enteropathogenic and enteroinvasive escherichia coli, and chlamydia spp.

Modified cationic liposome adjuvants

The present invention relates to the use of vaccines with adjuvants comprising cationic liposomes where neutral lipids has been incorporated into the liposomes to change the gel-liquid phase transition and thereby modifying the igg sub-type response and enhancing the cd8 response of the liposomal adjuvant. This technology can be used to increase the production of igg2 antibodies.

Tmem22 peptides and vaccines including the same

Isolated peptides composed of the amino acid sequence of seq id no: 33 or fragments thereof that bind to hla antigens and have cytotoxic t lymphocyte (ctl) inducibility and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines are described herein. The present invention further provides peptides that include one, two, or several amino acid insertions, substitutions or additions to the aforementioned peptides or fragments, but yet retain the requisite cytotoxic t cell inducibility.

C1orf59 peptides and vaccines including the same

The present invention provides isolated peptides having the amino acid sequence of seq id no: 43 or immunologically active fragments thereof, which bind to hla antigen and have cytotoxic t lymphocyte (ctl) inducibility. The present invention further provides peptides which include one, two, or several amino acid insertions, substitution or addition to the aforementioned peptides or fragments, but still have the cytotoxic t cell inducibility.

Sema5b peptides and vaccines including the same

As discussed in detail herein, isolated epitope peptides derived from sema5b bind to an hla antigen and induce cytotoxic t lymphocytes (ctl) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines. The inventive peptides encompass both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite hla binding and/or ctl inducibility of the original sequences.

Mphosph1 peptides and vaccines including the same

As discussed in greater detail herein, isolated epitope peptides derived from mphosph1 bind to an hla antigen and induce cytotoxic t lymphocytes (ctl) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines. The inventive peptides encompass both the above-mentioned mphosph1-derived amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite ctl inducibility of the original sequences.

Inhibitors of bacterial type iii secretion system

Organic compounds showing the ability to inhibit effector toxin secretion or translocation mediated by bacterial type iii secretion systems are disclosed. The disclosed type iii secretion system inhibitor compounds are useful for combating infections by gram-negative bacteria such as salmonella spp., shigella flexneri, psendomonas spp., yersinia spp., en tero pathogenic and enteroinvasive escherichia coli, and chlamydia spp.

Polynucleotides for the amplification and detection of chlamydia trachomatis and neisseria gonorrhoeae

Polynucleotides useful for detecting chlamydia trachomatis and/or neisseria gonorrhoeae in a test sample, kits, a nucleic acid amplification method and detection method including the same.. .

Chlamydia antigens

Chlamydia antigens (e.g., polypeptides, polypeptide fragments, and fusion proteins) are provided. Also provided are vaccines and pharmaceutical compositions for treating or preventing a bacterial infection, such as chlamydia, in a subject..

Nanoparticles for imaging and treating chlamydial infection

Compositions of nanoparticles and targeting moieties for imaging and treating chlamydial infection are provided, including nanoparticles conjugated to folic acid and comprising at least one antibiotic effective against chlamydia.. .

Tigecycline crystalline hydrate and preparation method therefor and use thereof

Provided are a tigecycline crystalline hydrate, and a preparation method therefor and use thereof. The crystalline hydrate has high stability for storage, and is used for the manufacture of a medicament for treating or preventing the infection of respiratory system, hepatobiliary system, facial features, urogenital system, bone and joint, skin and soft tissue and endocarditis, septicemia, meningitis caused by susceptible strains of gram-positive or gram-negative bacteria, anaerobic bacteria, chlamydia, and mycoplasma in human or animal..

Methods of detecting antibodies specific for denatured hla antigents

The invention is directed to methods of screening for hla antibodies comprising detecting antibodies specific for native hla antigens and denatured hla antigens. The invention also provides for methods of removing antibodies specific for denatured hla antigens or antibodies specific for native hla antigens from a serum sample.

Chlamydia antigens

The invention provides chlamydia antigens for use in the treatment, prevention and/or diagnosis of chlamydia infection. In particular, the invention provides antigens ct733, ct1 53, ct601, ct279, ct443, ct372, ct456, ct381, ct255, ct341, ct716, ct745, ct387, ct812, ct869, ct166, ct175, ct163, ct214, ct721, ct127, ct043, ct823 and/or ct600 from c.

Emp2 antibodies and their therapeutic uses

The present invention provides methods and compositions useful in the treatment or prevention of chlamydia infections and cancer. The methods and compositions inhibit the entry of chlamydia into a host cell expressing emp2 by interfering with the interaction between the chlamydia and emp2.

Vaccines against chlamydial infection

The present invention relates to compositions comprising proteins or polynucleotides of chlamydia sp., in particular combinations of proteins or polynucleotides encoding them, and methods for the use of the proteins or polynucleotides in the treatment, prevention and diagnosis of chlamydia infection.. .

Tomm34 peptides and vaccines including the same

The present invention provides isolated peptides or the fragments derived from seq id no: 42, which bind to an hla antigen and induce cytotoxic t lymphocytes (ctl). The peptides may include one of the above mentioned amino acid sequences with substitution, deletion, or addition of one, two, or several amino acids sequences.

Method for detecting nucleic acids

Method for detecting nucleic acids which employs a double-stranded oligonucleotide probe containing i) a first probe including a first label moiety, and ii) a second probe partially complementary with the first probe and including a second label moiety capable of interacting with the first moiety when brought in close proximity with each other, the second moiety being a quencher or acceptor of emission of the first moiety. The first or second probe includes a sequence complementary to that of a target nucleotide, and the second or first probe, respectively, includes a sequence complementary to a complement of the target nucleotide sequence of the nucleic acid to be detected.

Modulators of gtpase and use in relevant treatment

The present invention relates to molecules which function as selective modulators of the ras-homologous (rho) family of small gtpases, in particular, cdc42 gtpase and their use to treat diseases, for example cancers, including metastatic cancer, genetic and acquired diseases where activation of cdc42 gtpase plays a pivotal role, such as neurodegenerative diseases, rheumatoid arthritis, atherosclerosis, diabetes type i, autosomal polycystic kidney disease, cystic kidney disease, precystic kidney disease, microbial infections, including chlamydia infections, e. Coli infections, h.

Immunogenic compositions

The present invention provides compositions comprising a chlamydial major outer membrane protein (referenced herein as “momp”), from at least one chlamydial serovar and an adjuvant, characterized in that the adjuvant comprises the product e6020 having cas number 287180-63-6. The composition may further comprise at least one carrier system (e.g., emulsion, mineral particle).

Emp2 antibodies and their therapeutic uses

The present invention provides methods and compositions useful in the treatment or prevention of chlamydia infections and cancer. The methods and compositions inhibit the entry of chlamydia into a host cell expressing emp2 by interfering with the interaction between the chlamydia and emp2.

Wdhd1 peptides and vaccines including the same

Peptide vaccines against cancer are described herein. In particular, isolated epitope peptides or immunogenic fragments derived from seq id no: 32, that bind to an hla antigen and induce cytotoxic t lymphocytes (ctl) are provided.

Methods of using (4s,4as,5ar,12as)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide

A method of treating a bacterial infection, e.g., a bacterial infection with methicillin resistant staphylococcus aureus, helicobacter pylori, chlamydia trachomatis, or chlamydia pneumonia, comprising administering to a subject (4s,4as,5ar,12as)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide or a pharmaceutically acceptable salt thereof is disclosed. More specifically, a method of treating a bacterial infection comprising administering to a subject crystalline mono hydrochloride salt, crystalline mono mesylate salt or crystalline mono sulfate salt of (4s,4as,5ar,12as)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide is disclosed..

Methods and compositions for detecting serotypes of chlamydia trachomatis capable of causing lymphogranuloma venereum

Disclosed are methods and compositions for conducting assays utilizing real-time polymerase chain reactions (“pcrs”) in detection of serotypes l i, l ii, and l iii, but not stereotype b, of chlamydia trachomatis, capable of causing lymphogranuloma venereum (“lgv”). These assays take advantage of a deletion occurring in the cytotoxin gene locus specific to the l i, l ii, and l iii serotypes.

C18orf54 peptides and vaccines including the same

Peptide vaccines against cancer are described herein. In particular, isolated epitope peptides or immunogenic fragments derived from seq id no: 35, that bind to an hla antigen and induce cytotoxic t lymphocytes (ctl) are provided.

Bank of stem cells for producing cells for transplantation having hla antigens matching those of transplant recipients, and methods for making and using such a stem cell bank

Methods for producing stem cell banks, preferably human, which optionally may be transgenic, e.g., comprised of homozygous mhc allele cell lines are provided. These cells are produced preferably from parthenogenic, ivf, or same-species or cross-species nuclear transfer embryos or by dedifferentiation of somatic cells by cytoplasm transfer.

Assay for chlamydia trachomatis by amplification and detection of chlamydia trachomatis pmpa gene

A region of the chlamydia trachomatis pmpa gene has been identified which is useful for performing amplification assays to determine specifically whether c. Trachomatis is present in the sample being tested.

Methods and compositions for chlamydial antigens as reagents/strategies for diagnosis and treatment of chlamydial infection and disease

The present invention provides chlamydia proteins and methods of use in diagnostic and detection assays as well as in treatment and immunization protocols.. .

Emp2 antibodies and their therapeutic uses

The present invention provides methods and compositions useful in the treatment or prevention of chlamydia infections and cancer. The methods and compositions inhibit the entry of chlamydia into a host cell expressing emp2 by interfering with the interaction between the chlamydia and emp2.

Microbial assay

A method of detecting genetic material deriving from chlamydia trachomatis comprising detection of a specified nucleic acid sequence, optionally using specific primers and probes and optionally in combination with the detection of genetic material deriving from pectobacterium atrosepticum as an internal control; and related products and kits.. .

Omv vaccines

The invention is in the field of outer membrane vesicles (omv) and their uses. More particularly the present invention provides omv obtained from a bacterium being an ompa mutant and/or a mutant in one or more components of the tolpal complex and presenting a heterologous antigen on its surface.

Immunogenic compositions for chlamydia trachomatis

The invention relates to immunogenic compositions comprising combinations of chlamydia trachomatis antigens and their use in vaccines. The composition may comprise at least two components, one component of which comprises chlamydia trachomatis antigens for eliciting a chlamydia trachomatis specific th1 immune response and another component of which comprises antigens for eliciting a chlamydia trachomatis specific th2 immune response.

Chimeric momp antigen

The present invention regards polypeptides capable of eliciting an immunological response that is protective against chlamydia trachomatis. The polypeptide comprises a first amino acid sequence which has at least 90% homology with the amino acid sequence according to seq id no: 1 and a second amino acid sequence which has at least 90% homology with the amino acid sequence according to seq id no: 2.

Porin b (porb) as a therapeutic target for prevention and treatment of infection by chlamydia

The present invention features peptides of a porb polypeptide, which porb peptides are useful in production of antibodies that bind the full-length porb polypeptide and as a therapeutic agent. In specific embodiments the invention features a composition comprising one or more porb peptides (other than a full-length porb polypeptide), which peptides contain at least one epitope that can elicit chlamydia-neutralizing antibodies.

Chlamydia trachomatis antigens

Proteins encoded by chlamydia trachomatis which are immunogenic in humans as a consequence of infection have been identified using western blots of two-dimensional electrophoretic maps. Several known immunogens were identified, as were proteins not previously known to be immunogens, and proteins not previously reported as expressed gene products..





Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Hla for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Hla with additional patents listed. Browse our RSS directory or Search for other possible listings.


1.7142

file did exist - 4996

1 - 1 - 103